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Background
Angelman syndrome (AS) is a severe neurodevelopmental
disorder characterized by mental retardation, absence of
speech, ataxia, seizures and hyperactivity. Individuals
with AS lack a normal active maternal copy of the UBE3A
gene, encoding ubiquitin protein ligase (E6AP). In 80% of
patients the clinical diagnosis is verified by molecular
detection of one of the typical 15q11-q13 abnormalities,
including chromosomal deletions (70%), paternal unipa-
rental disomy (3- 5%) or imprinting centre mutations
(7%). Heterozygous loss- of- function mutations of E6AP
have been identified in approximately 8% of cases.
UBE3A gene is imprinted in human brain, with the pater-
nal allele being normally silenced. E6AP is a member of
E3 ubiquitin ligase protein family which plays a role in
defining substrate specificity of the ubiquitin- proteasome
degradation system. The exact mechanism by which the
defective E6-AP gene causes AS remains unknown. Clini-
cal findings seem to be due to failure to degrade various
proteins, accumulation of which may be harmful for an
individual.
Materials and methods
30 patients referred for AS, with no other molecular defect
identified, were screened for mutations in the UBE3A
gene (exons 9, 12, 15 and 16). Direct automated sequenc-
ing together with ECMA assay were performed in order to
identify mutations in this group of patients.
Results
No mutations were detected in any of the UBE3A exons
studied.
Conclusions
Further screening of all exons of UBE3A, as well as other
genes, related to AS- like phenotypes, such as MECP2
gene, will probably identify mutations, confirming the
clinical diagnosis and providing information about the
molecular mechanisms.
from International Society on Brain and Behaviour: 3rd International Congress on Brain and Behaviour
Thessaloniki, Greece. 28 November – 2 December 2007
Published: 17 April 2008
Annals of General Psychiatry 2008, 7(Suppl 1):S333 doi:10.1186/1744-859X-7-S1-S333
<supplement> <title> <p>International Society on Brain and Behaviour: 3rd International Congress on Brain and Behaviour</p> </title> <note>Meeting abstracts - A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1744-859X-7-S1-full.pdf">here</a>.</note> </supplement>
This abstract is available from: http://www.annals-general-psychiatry.com/content/7/S1/S333
© 2008 Tzagaraki et al.; licensee BioMed Central Ltd. 
